Overview

Determine the Effect of Multiple Doses of AZD7325, CYP Study

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
To determine the effects of repeated doses of AZD7325 on the pharmacokinetic profile of a CYP3A4 substrate (midazolam and its 1' hydroxy metabolite) and a CYP1A2 substrate (caffeine and its paraxanthine [3-desmethyl] metabolite).
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Caffeine
Midazolam